139 related articles for article (PubMed ID: 20651407)
1. Prognostic impact of CD133 expression in gastric carcinoma.
Ishigami S; Ueno S; Arigami T; Uchikado Y; Setoyama T; Arima H; Kita Y; Kurahara H; Okumura H; Matsumoto M; Kijima Y; Natsugoe S
Anticancer Res; 2010 Jun; 30(6):2453-7. PubMed ID: 20651407
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
3. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
[TBL] [Abstract][Full Text] [Related]
4. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Expression of Markers of Cancer Stem Cells in Gastric Adenocarcinoma and their Relationship to Vasculogenic Mimicry.
Zhou L; Yu L; Feng ZZ; Gong XM; Cheng ZN; Yao N; Wang DN; Wu SW
Asian Pac J Cancer Prev; 2015; 16(10):4177-83. PubMed ID: 26028069
[TBL] [Abstract][Full Text] [Related]
6. The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
Eto S; Yoshikawa K; Shimada M; Higashijima J; Tokunaga T; Nakao T; Nishi M; Takasu C; Sato H; Kurita N
Anticancer Res; 2015 Apr; 35(4):2071-6. PubMed ID: 25862862
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.
Zhao P; Li Y; Lu Y
BMC Cancer; 2010 May; 10():218. PubMed ID: 20487522
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.
Liu Q; Li JG; Zheng XY; Jin F; Dong HT
Chin Med J (Engl); 2009 Nov; 122(22):2763-9. PubMed ID: 19951611
[TBL] [Abstract][Full Text] [Related]
10. Sequential expression of putative stem cell markers in gastric carcinogenesis.
Wang T; Ong CW; Shi J; Srivastava S; Yan B; Cheng CL; Yong WP; Chan SL; Yeoh KG; Iacopetta B; Salto-Tellez M
Br J Cancer; 2011 Aug; 105(5):658-65. PubMed ID: 21829201
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
12. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
13. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
14. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma.
Yu JW; Zhang P; Wu JG; Wu SH; Li XQ; Wang ST; Lu RQ; Ni XC; Jiang BJ
J Exp Clin Cancer Res; 2010 Nov; 29(1):141. PubMed ID: 21054902
[TBL] [Abstract][Full Text] [Related]
15. Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization.
Sterlacci W; Savic S; Fiegl M; Obermann E; Tzankov A
J Thorac Oncol; 2014 Jan; 9(1):41-9. PubMed ID: 24346092
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of expression of CD133 and Ki-67 in gastric cancer.
Saricanbaz I; Karahacioglu E; Ekinci O; Bora H; Kilic D; Akmansu M
Asian Pac J Cancer Prev; 2014; 15(19):8215-9. PubMed ID: 25339008
[TBL] [Abstract][Full Text] [Related]
18. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients.
Tseng JY; Yang CY; Yang SH; Lin JK; Lin CH; Jiang JK
J Surg Res; 2015 Dec; 199(2):362-70. PubMed ID: 26119272
[TBL] [Abstract][Full Text] [Related]
19. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.
Horst D; Kriegl L; Engel J; Kirchner T; Jung A
Cancer Invest; 2009 Oct; 27(8):844-50. PubMed ID: 19626493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]